EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Impact of Vutrisiran on Exploratory Cardiac Parameters in Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Pablo Garcia-Pavia iD, Martha Grogan, Parag Kale, John L Berk iD, Mathew S Maurer, Isabel Conceição iD, Marcelo Di Carli, Scott D Solomon, Chongshu Chen, Elena Yureneva, John Vest, Julian D Gillmore

European Journal of Heart Failure · 01.02.2024 · 26 (2) · 397-410

DOI: 10.1002/ejhf.3138 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, online erschienen am 06.02.2024. Verfasst von Pablo Garcia-Pavia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain. Hauptthemen laut MEDLINE: Heart Failure, Amyloid Neuropathies, Familial, Polyneuropathies. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alnylam Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

HELIOS-A was a Phase 3, open-label study of vutrisiran, an RNA interference therapeutic, in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy. This analysis evaluated vutrisiran's impact on exploratory cardiac endpoints in HELIOS-A patients. Methods and results Patients were randomized 3:1 to subcutaneous vutrisiran 25 mg every 3 months or intravenous patisiran 0.3 mg/kg every 3 weeks (reference group) for 18 months. Exploratory cardiac endpoints included change from baseline in N-terminal prohormone of brain-type natriuretic peptide (NT-proBNP) and echocardiographic parameters versus external placebo (APOLLO study). The modified intent-to-treat (mITT) population comprised randomized patients receiving any study drug (n = 122). A cardiac subpopulation with evidence of cardiac amyloid involvement (n = 40) was prespecified. 99mTc scintigraphy exploratory assessments in a planned vutrisiran-treated cohort at select sites were compared with baseline. At Month 18, vutrisiran demonstrated beneficial effects on NT-proBNP versus external placebo in the mITT and cardiac subpopulations (adjusted geometric mean fold change ratio [95% confidence interval] 0.480 [0.383–0.600], p = 9.606 × 10−10 and 0.491 [0.337–0.716], p = 0.0004, respectively). Benefits or trends towards benefit in echocardiographic parameters versus external placebo were observed for both populations. In 99mTc scintigraphy assessments, 32/47 (68.1%) and 31/48 (64.6%) patients exhibited reduced normalized left ventricular total uptake and heart-to-contralateral lung ratio, respectively. Perugini grade was reduced or unchanged versus baseline in 55/57 (96.5%) evaluable patients. No increase in cardiac adverse events was observed with vutrisiran versus external placebo.

Conclusions

Vutrisiran demonstrated evidence of potential benefit on cardiac manifestations in patients with ATTRv amyloidosis with polyneuropathy, with an acceptable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureAmyloid Neuropathies, FamilialPolyneuropathiesHumansPrealbumin

Stichwörter der Autor:innen

99mTc scintigraphyCardiomyopathyEchocardiographyHereditary transthyretin‐mediated amyloidosisNT‐proBNPVutrisiran

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcon, Spain.
  • Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
  • Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TX, USA.
  • Amyloidosis Center, Boston Medical Center, Boston University, Boston, MA, USA.

ORCID-Profile: Pablo Garcia-Pavia, John L Berk, Isabel Conceição

Förderung

  • Alnylam Pharmaceuticals

Zitieren

APA

Garcia-Pavia, P., Grogan, M., Kale, P., Berk, J. L., Maurer, M. S., Conceição, I., Di Carli, M., Solomon, S. D., Chen, C., Yureneva, E., Vest, J., & Gillmore, J. D. (2024). Impact of Vutrisiran on Exploratory Cardiac Parameters in Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy. European Journal of Heart Failure, 26(2), 397-410. https://doi.org/10.1002/ejhf.3138

Vancouver

Garcia-Pavia P, Grogan M, Kale P, Berk JL, Maurer MS, Conceição I, et al. Impact of Vutrisiran on Exploratory Cardiac Parameters in Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy. European Journal of Heart Failure. 2024;26(2):397-410. doi:10.1002/ejhf.3138

BibTeX
@article{GarciaPavia2024,
  author = {Garcia-Pavia, Pablo and Grogan, Martha and Kale, Parag and Berk, John L and Maurer, Mathew S and Conceição, Isabel and Di Carli, Marcelo and Solomon, Scott D and Chen, Chongshu and Yureneva, Elena and Vest, John and Gillmore, Julian D},
  title = {Impact of Vutrisiran on Exploratory Cardiac Parameters in Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy},
  journal = {European Journal of Heart Failure},
  year = {2024},
  volume = {26},
  number = {2},
  pages = {397--410},
  doi = {10.1002/ejhf.3138}
}
Kostenlos starten →